Clinical Category: Metabolic Health & Medical Weight Management
Medically Reviewed By: Pharma Direct UK Clinical Team
Last Updated: September 28, 2026 (Compliance: MHRA & GPhC Standards)
For individuals struggling with chronic weight management or obesity-related health risks, injectable GLP-1 medications have reshaped UK clinical practice. Among the options available through registered online pharmacies, two treatments dominate patient inquiries: Mounjaro (Tirzepatide) and Wegovy (Semaglutide).
While both are administered as once-weekly subcutaneous injections, they rely on different active peptides and produce distinct average weight loss outcomes in clinical trials.
The Science: Single Agonist vs. Dual GIP/GLP-1 Agonist
Understanding how these medications regulate appetite, blood sugar, and satiety in the brain is key to choosing the right treatment:
- Wegovy (Semaglutide – GLP-1 Agonist): Mimics the single natural gut hormone GLP-1 (Glucagon-Like Peptide-1). It targets brain receptors that control appetite, delays gastric emptying (keeping you fuller for longer), and reduces cravings.
- Mounjaro (Tirzepatide – Dual GIP/GLP-1 Agonist): Acts on two hormone receptors simultaneously: GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide). This dual action enhances fat metabolism, improves insulin sensitivity, and exerts a stronger suppressive effect on appetite.
H2: Head-to-Head Comparison
| Clinical Feature | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
| Mechanism of Action | Single GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Average Weight Loss | ~15% of total body weight at 68 weeks | ~20.9% to 22.5% of total body weight at 72 weeks |
| Dosing Schedule | Once weekly (0.25mg up to 2.4mg maintenance) | Once weekly (2.5mg up to 15mg maintenance) |
| Administration | Pre-filled FlexTouch pen | Pre-filled KwikPen (UK 4-dose device) |
| Common Side Effects | Nausea, constipation, diarrhea, reflux | Nausea, diarrhea, decreased appetite, fatigue |
Key Differentiating Factors
1. Overall Efficacy and Fat Mass Reduction
Head-to-head clinical data (including the SURPASS and SURMOUNT trial series) indicate that Mounjaro’s dual-action mechanism delivers higher average percentage weight reduction compared to single GLP-1 agents like Wegovy.
2. Escalation Schedules and Tolerability
Both medications require a gradual 4-week dose escalation step to minimize gastrointestinal side effects. Starting at a lower dose allows your digestive system to adapt before moving to higher maintenance levels.
⚠️ Prescribing Eligibility: Under UK clinical guidelines, weight management injections are prescribed for patients with a BMI of 30 or higher, or a BMI of 27 or higher alongside weight-related comorbidities (such as hypertension or type 2 diabetes).
Can I switch directly from Wegovy to Mounjaro?
Yes, patients can transition between treatments under medical supervision. However, because they use different active ingredients, you cannot switch directly to an equivalent high dose; prescribers will typically reboot or recalibrate your escalation schedule.
How long do I need to stay on weight loss injections?
GLP-1 treatments are designed for chronic weight management. Stopping treatment usually causes hunger hormones to return to baseline levels, which can lead to weight regain if long-term lifestyle and dietary changes are not maintained.
Do these pens require refrigeration?
Yes. Unopened pens must be stored in a refrigerator (2°C to 8°C). Once in use, pens can be kept at room temperature (below 30°C) for up to 30 to 56 days depending on the specific brand guidelines.
How do I request an online clinical consultation?
You can complete an online health and BMI assessment. At Pharma Direct UK, our prescribers review your medical history and weight goals to ensure your chosen treatment is safe and suitable before dispensing.